Concord Biotech Limited — Financials & Forensics
Sector: Healthcare · NSE: CONCORDBIO · BSE: 543960 · ISIN: INE338H01029
11 Sep 2026
Add CONCORDBIO to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from operations | ₹1,017 Cr | ₹1,200 Cr | ₹1,055 Cr |
| EBITDA | ₹432 Cr | ₹506 Cr | ₹367 Cr |
| EBITDA margin | 42.4% | 42.2% | 34.8% |
| Profit after tax | ₹308 Cr | ₹372 Cr | ₹261 Cr |
Deeper analysis
Recent filings by Concord Biotech Limited
-
Newspaper publication cutouts of unaudited Standalone and Consolidated Financial results for the fir
01 Aug 2026 · Financial Results
-
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2
31 Jul 2026 · General Update
-
We would like to inform you that the Board of Directors of the Company, at its meeting held today i.
31 Jul 2026 · Financial Results
Never miss a filing again
About Concord Biotech Limited on Indian Stock Alerts
Indian Stock Alerts tracks Concord Biotech Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.